The slip-up on the secondary neurocognitive endpoint in Biomarin Pharmaceutical Inc.'s pivotal phase III PRISM-2 study in phenylketonuria (PKU) with pegvaliase, also known as Peg-Pal, probably matters less than the win with regard to phenylalanine (Phe) levels, analysts figure – and may not have been much of a miss anyway.